Moreover, clinical data indicate that despite the fact that STK11-mutated tumours usually exhibit high TMB levels, which are considered to be associated with a favourable response to immunotherapy, these tumours have worse response rates to immunotherapy and are associated with poor prognosis in NSCLC [46]. Here, STK11 is linked to non-small cell lung carcinoma.